The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma.
CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans.
There is a critical need for reliable and easily accessed liver disease diagnosis. Yet, no accurate point-of-care testing is currently available in the diagnostic market.
Nonalcoholic steatohepatitis (NASH), the progressive form of Non-alcoholic fatty liver disease (NAFLD), can lead to cirrhosis, cardiovascular problems, hepatocellular carcinoma, and even death. Liver disease is reversible if detected early on. If diagnosed in advanced stages, it often cannot be cured.
Livivos’s technology transforms liver disease diagnostics, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support accurate evaluation of the response to treatments.
Existing diagnostic options for fatty liver disease either require specialized facilities (MRI), are intrusive and painful (biopsy), or have limited accuracy (ultrasound-based methods). Livivos offers a much-needed alternative with its accurate, non-invasive, and point-of-care solution.
There are 64 million individuals with NAFLD in the United States and 52 million total in Germany, France, Italy, and the UK. The global prevalence of NAFLD is estimated to be 24%. 1.75 million individuals die of liver disease each year. In addition, a high prevalence of obesity has been reported in South America, Asia, and the Middle East. The number of affected people and the economic burden are expected to increase.
Current NAFLD trends indicate that the disease will soon be the leading cause of liver transplant. There is a rapid increase in the number of drugs targeting this disease that are undergoing clinical trial. The critical prevalence of fatty liver disease comes with an associated annual direct medical cost of over $100 billion, in the United States alone, with a significantly higher burden when societal costs are included.
Source: Gut 69(3):564, 2020.
The diagnosis of NAFLD and NASH is hindered by the limitations of traditional diagnostic methods. An accurate and non-invasive diagnostic approach is crucial to reversing the trend of these diseases. Livivos offers a solution, providing high accuracy in point of care settings. With LiverScope®, there is now the potential to reverse the upward trend of liver disease and provide early and effective intervention.
Read: Gut 69(3):564, 2020.
Preventive medicine, clinical triage for the millions of patients with suspected NAFLD, and accurate over-time treatment monitoring.
Supporting regulatory clinical trials. There is a rapid increase in the number of liver disease drugs undergoing FDA evaluation. Livivos’s technology provides biomarkers to quantify the evolution of steatosis.
Monitoring of drug effectiveness after drug approval – especially for NASH drugs with anti-steatotic mechanisms of action – as they enter the clinical market.